Some impressive results are coming out of Retatrutide's Phase 3 trials. We're seeing participants on the highest dose achieve an average 28.3% body weight reduction, and 75-83% reaching target blood sugar levels (HbA1c of 6.5% or less).
Triple-Agonist Drug Retatrutide Shows Striking Weight Loss and Blood Sugar Improvement in Pivotal PhRetatrutide, a new "triple G" drug that activates three different hormone receptors (GLP-1, GIP, and glucagon), has demonstrated impressive results in its Phase 3 clinical trials. It led to significanlifesciencedaily.news